Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Nuvation Bio Inc
(NY:
NUVB
)
3.220
+0.020 (+0.63%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nuvation Bio Inc
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
July 23, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
June 01, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
April 10, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
March 28, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
March 25, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
March 14, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
March 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END
Via
FinancialNewsMedia
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
January 08, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
January 08, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Departure of Chief Financial Officer
November 13, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
June 01, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 15, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
December 19, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 03, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
August 01, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
July 18, 2022
From
Nuvation Bio Inc.
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm
June 30, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm
June 29, 2022
From
The Schall Law Firm
Via
Business Wire
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
June 27, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
May 09, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.